Clinical diagnosis, treatment, and survival analysis of 61 cases of salivary duct carcinoma: a retrospective study
Objective This study aims to investigate the clinicopathological features, treatment modalities, and prognostic factors associated with salivary duct carcinoma (SDC). Methods A retrospective analysis was conducted on the clinicopathological data of 61 patients with SDC admitted to Shanxi Cancer Hosp...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2025-07-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/19626.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective This study aims to investigate the clinicopathological features, treatment modalities, and prognostic factors associated with salivary duct carcinoma (SDC). Methods A retrospective analysis was conducted on the clinicopathological data of 61 patients with SDC admitted to Shanxi Cancer Hospital from January 2010 to February 2024. This study focused on their demographic information, treatment regimens, clinical outcomes, and overall prognosis. Results A total of 61 patients with SDC were included in this study, of whom 45 (73.77%) had primary tumors in the parotid gland, 44 (72.13%) were in stage IV at the initial visit, 35 (57.38%) had cervical lymph node metastases, and two (3.28%) had distant metastasis at the first visit. Immunohistochemical (IHC) staining showed that 54 cases (88.52%) were positive for androgen receptor (AR), and 25 cases (40.98%) were positive for human epidermal growth factor receptor 2 (HER-2). Two patients did not undergo surgical treatment due to distant metastasis and received palliative chemoradiotherapy. Fifty-nine patients underwent radical surgery, and of these, 52 (88.14%) received postoperative adjuvant treatment, including chemoradiotherapy or radiotherapy alone. The median overall survival (OS) time was 20 months for the non-surgery group (n = 2), 79 months (95% CI [72.60–85.40]) for the surgery and chemoradiotherapy group (n = 22), 61 months (95% CI [49.11–72.90]) for the surgery and radiotherapy group (n = 30), 20 months (95% CI [13.60–26.40]) for the surgery-only group (n = 7). The median OS was significantly higher in the adjuvant treatment groups (radiotherapy or chemoradiotherapy) compared with the surgery only or non-surgery groups (P < 0.05). Conclusion SDC is a rare and highly aggressive malignancy with a poor prognosis. Surgical margins, American Joint Committee on Cancer (AJCC) stage, and treatment method were identified as adverse prognostic factors affecting the OS of patients with SDC. Radical surgery remains the primary treatment for salivary duct carcinoma while adjuvant therapy significantly reduces recurrence rates and improves survival. However, the overall prognosis remains challenging, highlighting the need for novel therapeutic strategies. |
|---|---|
| ISSN: | 2167-8359 |